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Edited by Beat ImhofAbstract Several recent papers support the involvement of an
interaction between stromal cell-derived factor-1 (SDF-1/
CXCL12) and its receptor, chemokine receptor CXCR4, in
memory T cell migration in the inﬂamed rheumatoid arthritis
(RA) synovium. Analogs of the 14-mer peptide T140 were
previously found to be speciﬁc CXCR4 antagonists that were
characterized as not only HIV-entry inhibitors but also anti-
cancer-metastatic agents. In this study, a T140 analog, 4F-
benzoyl-TN14003, was proven to inhibit CXCL12-mediated
migration of human Jurkat cells and mouse splenocyte in a dose-
dependentmanner in vitro (IC50 = 0.65 and 0.54 nM, respectively).
Furthermore, slow release administration by subcutaneous injec-
tion (s.c.) of 4F-benzoyl-TN14003 using an Alzet osmotic pump
signiﬁcantly suppressed the delayed-type hypersensitivity re-
sponse induced by sheep red blood cells in mice, and signiﬁcantly
ameliorated clinical severity in collagen-induced arthritis in mice.
As such, T140 analogs might be attractive lead compounds for
chemotherapy of RA.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inﬂammatory cytokines, such as IL-1, IL-6, IFN-c and tu-
mor necrosis factor (TNF)-a, and activation markers play a
central role in the chronic rheumatoid arthritis (RA) synovium
[1]. Development of biological drugs targeting these cytokines,
such as humanized monoclonal antibodies, has produced
promising results in clinical therapy of RA patients. However,
this therapy has not yet reached a stage of perfection, and
development of other drugs with novel action mechanisms that
are independent of the above cytokine’s functions, is required
for the improvement of RA chemotherapy. Intrinsically, RA is
caused by the CD4þ memory T cell accumulation in the in-
ﬂamed synovium. Nanki et al. [2] reported that the memory T
cells highly express a chemokine receptor CXCR4, and that the* Corresponding authors. Fax: +81-75-753-4570.
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doi:10.1016/j.febslet.2004.05.056concentration of stromal cell-derived factor-1 (SDF-1/
CXCL12), an endogenous ligand of CXCR4, is extremely high
in the synovium of RA patients compared to controls. They
also found that CXCL12 stimulates migration of the memory
T cells and inhibits T cell apoptosis, suggesting that the
CXCL12–CXCR4 interaction plays an important role in T cell
accumulation in the RA synovium. Since chemokine CXCL12
[3–6] is independent of the inﬂammatory cytokines such as
TNF-a, in terms of its expression and action, development of
substances that inhibit the CXCL12–CXCR4 interaction
might be promising as drugs. We have developed several
CXCR4 antagonists, T22 (an 18-mer peptide) [7], T140 (a 14-
mer) [8] and FC131 (a cyclic pentapeptide) [9]. These peptides
have inhibitory activity against entry of T-cell line-tropic (X4-)
HIV-1 into target cells [7,10,11] as well as against cancer me-
tastasis and progression in breast cancer [12], pancreatic cancer
[13,14], melanoma [15], acute lymphoblastic leukemia [16],
small cell lung cancer [17], etc. In this study, we investigated
whether a bio-stable T140 analog, 4F-benzoyl-TN14003 [18],
shows anti-RA activity in the following experiments: inhibition
assays of Jurkat cell/splenocyte migration mediated by
CXCL12 in vitro, the delayed-type hypersensitivity (DTH)
response induced by sheep red blood cells (SRBC) in vivo and
collagen-induced arthritis (CIA) in vivo.2. Material and methods
2.1. Material
4F-benzoyl-TN14003 [4-ﬂuorobenzoyl–Arg–Arg–Nal–Cys–Tyr–
Cit–Lys–D–Lys–Pro–Tyr–Arg–Cit–Cys–Arg–NH2, a disulﬁde bond
between Cys4–Cys13, Nal¼ L-3-(2-naphthyl)alanine, Cit¼ L-citrulline]
was previously synthesized [18,19].
2.2. Migration assay of human Jurkat cells
Human Jurkat cells were obtained from the American Type Culture
Collection (Manassas, VA, USA), and cultured in RPMI-1640 medium
(BioWhittaker, Walkersville, MD, USA) supplemented with 10% fetal
calf serum (BioWhittaker).
Jurkat cells (2.5 106 cells/ml) were pre-incubated with various
concentrations of 4F-benzoyl-TN14003 at 37 C for 30 min. Then 200
ll of this suspension was placed into Transwell (Corning-Costar,
Cambridge, MA, USA) culture inserts within 24-well culture plates
containing 600 ll of assay medium (RPMI-1640/0.5% BSA/50 mmol/l
HEPES) with 10 ng/ml human CXCL12 (Genzyme Techne, Minne-
apolis, MN, USA). The plates were incubated at 37 C for 4 h in a
humidiﬁed 5% CO2 incubator. After the incubation, the culture insertsblished by Elsevier B.V. All rights reserved.
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counted using a Coulter counter. Percent migration was based on the
total initial input per well.2.3. Mouse splenocyte preparation and migration assay
Spleens were isolated from BALB/c mice (male, Charles River,
Yokohama, Japan), and single-cell suspensions prepared from spleens
were incubated in RBC lysing buﬀer (Immuno-Biological Laborato-
ries, Fujioka, Japan), washed twice with PBS and then resuspended in
assay medium.
Chemotaxis was measured in a 2.5-h Transwell migration assay as
described above. Recombinant mouse CXCL12 (100 ng/ml, Pepro-
Tech, London, UK) was added to the wells in chemotaxis medium, and
1 107 cells were added to the Transwell inserts. Migrated cells were
counted with a Coulter counter.2.4. Inhibition assay of the mouse DTH response
SRBC were washed twice with saline, and then resuspended in saline.
BALB/c mice (male 6 weeks, Charles River) were sensitized with a
subcutaneous injection of 5 107 SRBC in 50 ll of saline into the left
hind footpad. Five days later, mice were challenged by subcutaneously
injecting 1 108 SRBC in 50 ll of saline into the right hind footpad.
The thickness of the right hind paw was measured with a micrometer
(Mitutoyo, CD-15B, Kawasaki, Japan) before treatment and 24 h after
challenge. The DTH reaction was expressed as the swelling of the right
footpad.Fig. 1. Eﬀects of 4F-benzoyl-TN14003 on CXCL12-induced migration
of human Jurkat cells (A) and mouse splenocytes (B). Both cells were
treated by CXCL12 (human CXCL12 10 ng/ml for Jurkat cells, mouse
CXCL12 100 ng/ml for splenocytes) and various concentrations of 4F-
benzoyl-TN14003. Control migrating cells in the absence and presence
of CXCL12 are shown as ()) and (+), respectively. Data are expressed
as means ðn ¼ 2Þ.2.5. Induction and evaluation of CIA
Bovine type II collagen (CII, Collagen Research Center, Tokyo,
Japan) was dissolved in 0.05 mol/l acetic acid to a concentration of 2
mg/ml, and the emulsion was prepared with an equal volume of Fre-
und’s complete adjuvant (Difco, Detroit, MI, USA).
Six week-old male DBA/1J mice (Charles River) were injected in-
tradermally at the base of the tail with a volume of 50 ll of the above
emulsion. Twenty-one days after immunization, mice were given
booster shots with the CII emulsion in the same manner. Following
this injection, mice were evaluated for the incidence and the severity of
arthritis, body weight and the thickness of the hind ankles, twice a
week. At the end of the experimental period (2 weeks after the second
injection), sera were obtained and the weights of the 4 limbs were
measured.
The clinical severity of the arthritis was graded on a scale of 0–3 for
each paw as follows: 0, normal; 1, swelling of one digit or mild swelling
of the paw; 2, swelling of multiple digits or moderate swelling of the
entire paw; 3, severe swelling of the entire paw. Each mouse could
achieve a maximum score of 12.2.6. Measurement of serum anti-bovine CII antibody
Levels of serum anti-bovine CII IgG2a antibody were measured
using an ELISA assay. 96-well immunoplates were coated with bovine
CII (10 lg/ml in PBS) and incubated at 4 C overnight. Non-speciﬁc
binding was blocked with PBS containing 10% FCS for 2 h. Mouse
serum samples diluted with 10% FCS in PBS (1:1000) were added to
the wells and incubated at room temperature for 2 h. Horseradish
peroxidase-conjugated rat anti-mouse IgG2a antibody (1:1000 diluted,
Zymed Laboratories, South San Francisco, CA, USA) was added and
incubated for 1 h. 3,30,5,50-Tetramethylbenzidine (TMB) substrate
solution (DAKO A/S, Glostrup, Denmark) was added and allowed to
react for 30 min. The reaction was stopped by the addition of an equal
volume of 1 mol/l H2SO4, and the optical density at 450 nm was
measured using a microplate reader (Labsystems MultiscanMS, Hel-
sinki, Finland). For this ELISA, the wells were washed with PBS
containing 0.1% Tween 20 before each step.Fig. 2. Inhibition of the mouse DTH response by 4F-benzoyl-
TN14003. The gain of thickness of right footpad by swelling 24 h after
challenge was measured by a micrometer. PBS (control models) or 4F-
benzoyl-TN14003 (4.8, 24 or 120 lg/day) was administered by s.c.
injection using an Alzet pump from the day before immunization.
Data are expressed as meansS.E. ðn ¼ 7Þ. * P 6 0:025 (Williams’
test).2.7. Drug administration
4F-benzoyl-TN14003 was dissolved in PBS, and subcutaneously
administered using Alzet osmotic pumps (DURECT Corp., Cupertino,
CA, USA), which were implanted dorsalaterally under the skin at the
day before immunization (DTH) or the booster (CIA). In the experi-
ment of DTH and CIA, #1007D pumps (delivering 4.8, 24 and 120 lg/
day of 4F-benzoyl-TN14003 for 7 days) and # 2002 ones (delivering120 lg of 4F-benzoyl-TN14003 daily for 14 days) were used, respec-
tively. Indomethacin (1 mg/kg, Sigma Chemicals Co., St. Louis, MO,
USA), methotrexate (3 mg/kg, Wako Pure Chemical Industries, Ltd,
Osaka, Japan) and FK-506 (10 mg/kg, puriﬁed in Takeda Chemical
Industries, Ltd, Osaka, Japan) were orally administered once daily for
2 weeks from the day of booster. These drugs were suspended in a 0.5%
methylcellulose solution.2.8. Statistical analysis
The values were represented as the meansS.E. Statistical diﬀer-
ences were determined using an analysis of variance (ANOVA, SAS
software, version 6.1, SAS Institute, Cary, NC, USA). Results of DTH
were assessed with the one-tailed Williams’ test. A value of P 6 0:025
was considered statistically signiﬁcant. In the experiment involving
CIA, unpaired or paired t-test were applied when only two values sets
were compared. When data involved three or more groups, statistical
analysis was performed using Dunnett’s test. Clinical scores for each
group were compared using the non-parametric Steel test or the Wil-
coxon rank-sum test. The level of signiﬁcance was deﬁned as P 6 0:05
and P 6 0:01.
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3.1. Inhibition of migration of human Jurkat cells and mouse
splenocytes
Both human Jurkat cells and mouse splenocytes express
CXCR4 on their surfaces [12,20]. CXCL12 (10 ng/ml¼ 1.1
nM for Jurkat cells, 100 ng/ml¼ 11 nM for splenocytes)
dramatically enhanced the migration of Jurkat cells and0
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Fig. 3. Suppression of CIA in mice by 4F-benzoyl-TN14003. The incidence
evaluated, and body weight (C) and the thickness of the hind ankles (D) were
limbs were measured 2 weeks after the second immunization (E). Levels of a
after the second immunization, were measured by ELISA (F). PBS (contro
administered by s.c. injection using an Alzet pump from the day before the
munized. Data are expressed as means S.E. # #P 6 0:01 (t-test): comparis
models (Scores were compared by non-parametric Steel test).splenocytes, as compared to control (absence of CXCL12,
Fig. 1). 4F-benzoyl-TN14003 inhibited CXCL12-induced
migration of these cells in a dose-dependent manner. At a
concentration of 10 nM, 4F-benzoyl-TN14003 showed ap-
proximately 100% inhibition of cell migration induced by
CXCL12 (1.1 nM for Jurkat cells, 11 nM for splenocytes).
The IC50 values were determined to be 0.65 nM and 0.54
nM, respectively.Days after 2nd immunization
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(A) and the score expressing the clinical severity (B) of arthritis were
measured after the second immunization twice a week. The weights of 4
nti-bovine CII IgG2a antibody in serum, which was obtained 2 weeks
l models, n ¼ 12) or 4F-benzoyl-TN14003 (120 lg/day, n ¼ 11) was
second immunization. In normal models (n ¼ 8), mice were not im-
on with normal models, **P 6 0:01 (t-test): comparison with control
102 H. Tamamura et al. / FEBS Letters 569 (2004) 99–1043.2. Reduction of the DTH reaction in mice by subcutaneous
administration of 4F-benzoyl-TN14003 using Alzet osmotic
pumps
The SRBC-induced DTH reaction in mice was adopted as
an in vivo experimental model of the cellular immune response
for evaluation of 4F-benzoyl-TN14003 activity. The DTH re-
action was estimated as the gain of right footpad thickness
from swelling, 24 h after challenge. Seven mice were adminis-
tered PBS as control models and showed signiﬁcant footpad
swelling (Fig. 2). Twenty one mice were administered 4F-
benzoyl-TN14003 by s.c. injection using Alzet pumps (deliv-
ering 4.8, 24 and 120 lg/day, each for 7 mice) beginning from
the day before immunization. Treated mice showed a dose-
dependent suppression of swelling, as compared to control
mice. The 24 and 120 lg daily injections showed inhibitory
percentages of 31% and 51%, respectively. 4F-benzoyl-
TN14003 signiﬁcantly reduced the DTH reaction in mice.
3.3. Suppression of CIA in mice by subcutaneous administration
of 4F-benzoyl-TN14003 using Alzet osmotic pumps
In the next phase, CIA was adopted to provide a second in
vivo mouse model of this pathogenesis. During the 2 weeks
after the CII emulsion booster, the following data were col-
lected: the arthritis incidence, the scores expressing the sever-
ity, the body weight and thickness of the hind ankles were
observed twice a week; the 4 limbs’ weights and the serum anti-
bovine CII antibodies were measured on the 14th day. Eleven
mice were administered 4F-benzoyl-TN14003 by s.c. injection
using Alzet pumps (delivering 120 lg/day), beginning from theFig. 4. Reduction of ankle swelling in mouse CIA by 4F-benzoyl-
TN14003. Representative hind ankles of mice 2 weeks after the second
immunization are shown. Upper, 4F-benzoyl-TN14003 was adminis-
tered by s.c. injection using an Alzet pump from the day before the
second immunization; Lower, PBS was administered as control models.day before the booster. Twelve mice were administered PBS as
control models. Eight mice were not immunized as normal
models. After observation for 14 days, 4F-benzoyl-TN14003-
treated mice showed signiﬁcant suppression of several symp-
toms of arthritis (score increase, body weight loss, ankle
swelling and limbs’ weight gain) as compared to the control
mice that developed arthritis (Figs. 3 and 4). 4F-benzoyl-
TN14003-treated mice also showed an apparent suppression of
the extreme increase in levels of serum anti-bovine CII IgG2a
antibody observed for the control group (Fig. 3F).
In a further comparative study, indomethacin [21] (1 mg/kg),
methotrexate [22] (3 mg/kg) and FK-506 [23] (10 mg/kg),
which are clinically used for treatment of RA patients or are
known as anti-RA agents, were orally administered once daily
for 2 weeks from the day of the booster (Fig. 5). These treated
mice showed signiﬁcant suppression of ankle swelling and limb
weight gain, and an apparent suppression of marked increases
in arthritis scores and anti-bovine CII antibody levels, re-
markably similar to the results with 4F-benzoyl-TN14003.
Therefore, 4F-benzoyl-TN14003 can be seen to possess in-
hibitory activity against RA symptoms, comparable to these
known drugs.4. Discussion
Chemokines constitute a chemotactic cytokine family that
attract and induce migration of leukocytes, playing a funda-
mental role in the physiology of inﬂammation. CXCL12 is a
chemokine that recognizes CXCR4. CXCR4 also has signiﬁ-
cant involvement in several pathological conditions, including
AIDS [24], cancer [12–17,25] and RA [2]. The pathological
importance of CXCR4 derives from its initial identiﬁcation as
the second receptor involved in the X4-HIV-1 entry into T cells
[24]. According to recent reports, CXCL12 induces migration
of several types of cancer cells via CXCR4 on their cell sur-
faces, causing cancer metastasis and progression [12–17,25].
Furthermore, the CXCL12/CXCR4 axis is thought to play an
important role in the rheumatoid T cell accumulation in RA,
as described in Section 1 [2]. Thus, CXCR4 represents an
important therapeutic target for these diseases. We have pre-
viously developed several CXCR4 antagonists, T22, T140, 4F-
benzoyl-TN14003 and FC131, which have strong anti-HIV-1
and anti-cancer metastatic activities, as described in Section 1
[7–17]. De Clercq’s group reported another CXCR4 antago-
nist, AMD3100, which also has strong anti-HIV-1 activity [26].
Recently, he and his colleagues have found that AMD3100
inhibits autoimmune joint inﬂammation in IFN-c receptor-
deﬁcient mice, and that AMD3100 interferes with cellular
DTH reaction, but not with the humoral immune response to
CII in CIA, as assessed by measuring anti-CII antibody levels
[20]. In this study, we investigated whether 4F-benzoyl-
TN14003 shows anti-RA activity by assessing its eﬀects on
humoral and cellular immunity.
We previously reported that 4F-benzoyl-TN14003 has strong
binding capacity to CXCR4, as shown by inhibition of [125I]-
CXCL12 binding to CXCR4-expressing human Jurkat cells
(IC50¼ 0.99 nM) [12]. In this study, 4F-benzoyl-TN14003 was
clearly shown to inhibit CXCL12-induced migration of Jurkat
cells in a dose-dependent manner at subnanomolar levels, and
also to inhibit mouse splenocyte migration induced by
CXCL12. These results suggest that the activity of this com-
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mology of human and mouse CXCR4 [27]. Evaluation of the
inhibitory activity of 4F-benzoyl-TN14003 against CXCL12-
induced migration of CXCR4-expressing T cells suggests that
4F-benzoyl-TN14003 inhibits CXCL12-stimulated migration
of memory T cells, thereby suppressing accumulation of T cells
caused by inhibition of their apoptosis in the inﬂamed synovium
of RA patients. Therefore, we investigated the inhibitory eﬀects
of 4F-benzoyl-TN14003 against RA using two mouse experi-
mental models: the DTH response and CIA.
To evaluate the eﬀect of 4F-benzoyl-TN14003 on cellular
immunity, the DTH reactivity induced by SRBC was examinedin mice. Subcutaneous administration of 4F-benzoyl-TN14003
using Alzet osmotic pumps signiﬁcantly suppressed the foot-
pad swelling. This indicates that 4F-benzoyl-TN14003 inter-
feres with cellular immunity such as DTH, suggesting that
CXCR4 might play an important role in cellular immunity.
Next, the activity of 4F-benzoyl-TN14003 was assessed in the
CIA experiment, anRAanimalmodel. The levels of several CIA
symptoms were signiﬁcantly lower in 4F-benzoyl-TN14003-
treated mice than those in PBS-treated mice (arthritic control
mice). Serum levels of the anti-CII IgG2a anti-body were also
apparently lower in 4F-benzoyl-TN14003-treated mice. 4F-
benzoyl-TN14003 therefore interfereswith the humoral immune
104 H. Tamamura et al. / FEBS Letters 569 (2004) 99–104response to CII, in contrast to AMD3100 [20]. The diﬀerences in
the actions of AMD3100 and 4F-benzoyl-TN14003 in humoral
CIA immunity might be explained by a diﬀerence in the binding
sites of these CXCR4 antagonists [28] or by diﬀerences in the
CIA models that were used.
In conclusion, the present results suggest that a bio-stable
T140 analog, 4F-benzoyl-TN14003, inhibits the migration and
accumulation of rheumatoidT cells through a speciﬁc binding to
CXCR4 in competition with CXCL12. This compound inter-
fered with cellular and humoral immune responses in experi-
mental arthritis models in mice, and showed inhibitory eﬀects
against the CIA development at levels comparable to, or above
those of known drugs. Since T140 is an inverse agonist, which
has no CXCL12-like agonistic activity [29], it and its analogs
have the potential of becoming promising agents for RA che-
motherapy as well as for AIDS and cancer chemotherapy.
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